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calculated by using the human capital approach. Costs were
discounted at 5%. Annual and lifetime direct and indirect costs,
in US dollars (USD), were determined on a per patient basis,
and were then projected to the overall Colombian type-2 dia-
betes mellitus population. RESULTS: The estimated annual
total cost of type 2 diabetes mellitus was $2.7 billion USD from
the societal perspective. From the ministry of health perspec-
tive, the annual estimated cost was $921 million USD. The
annual direct cost per patient was $288 USD, and the annual
indirect cost per patient was $559 USD The distribution of this
cost over the different model disease stages was as follows: dia-
betes treatment, 47%; cardiac and coronary disease, 24%;
stroke, 15%; retinopathy, 2%, nephropathy 3%; and amputa-
tion, 9%. Macrovascular complications comprised 86% of the
annual direct costs and 95% of the annual indirect costs of
type 2 diabetes mellitus. CONCLUSION: The economic burden
of type 2 diabetes mellitus in Columbia is comparable to results
for other countries. The developed model showed a logical
disease progression.
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OBJECTIVES: To analyze the clinical and economic impact of
adequate control of glycosylated hemoglobin (HbA1c) over the
chronic complications of Type-2 Diabetes mellitus. METHODS:
A Monte Carlo simulation was performed termed Diabetes Mel-
litus Model (DMM), previously validated, and published. The
inﬂuence parameter of DMM was (HbA1c) simulated for each
patient. A temporary horizon of ﬁve years was set. The design
compared two hypothetical groups of 1000 patients each, with
identical parameters. Group one included patients not respond-
ing to conventional treatment with insulin, who initiated with a
serum level of 9.1% of HbA1c the ﬁrst year and remained at this
value during the four following years. This HbA1c value corre-
sponds to the average level seen in the Mexican population when
initially treated (ﬁrst level of attention). Group two included
patients responding to intensive treatment with insulin, who
initiated with 9.1% HbA1c and reached an average value of
7.5% HbA1c. The cost of complications was calculated through
the estimation of the direct cost. RESULTS: There were 209.69
events in group one, and 160.44 events in group two, a difference
of 43.65. There were 7.01 more hypoglycemic events in the
group two. Group one had 17.01 more cases of clinical neuropa-
thy, with an estimated cost of €1715.51 per/event. For diabetic
foot syndrome there were 2.31 more in group one with a cost of
€5180.35 annually. The model projected more cases of microal-
buminuria, who without adequate treatment would progress to
advanced renal disease, and 1.61 more events of advanced renal
disease with an annual cost of €22,273.35. CONCLUSION: The
model results justify prevention measures in the ﬁrst level of
attention emphasizing in the strict metabolic control to reduce
the start of the micro-vascular damage of target organs; reducing
the demand of hospitalization, labor incapacities and use of
high-specialty medications which represent the highest costs of
the health system.
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OBJECTIVES: To estimate the impact of achieving the American
Diabetes Association (ADA) goal for glycemic control
(HbA1c < 7.0%) on long-term costs associated with managing
the complications of Type II diabetes. The ADA also sets goals
for blood pressure (systolic <130 mmHg and diastolic
<80 mmHg), lipids (LDL-C < 100 mg/dL, HDL-C > 40 mg/dL
men, 50 mg/dL women, triglycerides <150 mg/dL). There is evi-
dence many do not achieve these targets, and have sub-optimal
control of cardiovascular risk factors. METHODS: A discrete
event simulation of the long-term economic impact of complica-
tions (cardiovascular and microvascular) for patients with Type
II diabetes was developed. Model parameters and risk functions
for complications were based on the UKPDS, Saskatchewan
health database analyses, and literature. A cohort is created by
reading in proﬁles including age (mean 59.3 years), gender (57%
male), blood pressure (mean SBP 132 mmHg), and lipids (mean
total cholesterols 5.32 mmol/L) extracted from patients with
Type II diabetes diagnosed for less than 5 years in NHANES
2001–2002. Two cohorts were simulated with HbA1c less than
and above 7%. One hundred replications of 1000 patients were
run over 20 years. Direct medical costs reported in 2004USD ($)
include hospital admission, outpatient, and routine care.
RESULTS: The average cost per patient who were above goal
(mean baseline HbA1c 9%) over 20 years was predicted at
$38,137 compared to $26,882 for patients at goal (mean base-
line HbA1c 6%). Complication rates were lower in patients at
goal: 29% fewer cardiovascular and 36% fewer microvascular
complications. Average life expectancy was 13.49 years, 0.44
years longer than those not at goal. Although over the ﬁrst 10
years, cardiovascular related costs were majority of the total
costs accrued, microvascular complications developed later in the
course of diabetes and their costs became majority over 20 years.
CONCLUSION: Patients achieving the recommended glycemic
goals are expected to substantially decrease complication costs
and complications rates.
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OBJECTIVES: To quantify the true cost of insulin prescribing in
type 2 diabetes (T2D) including insulin and insulin ancillary
items. Few data on annual insulin cost exist. Insulin is difﬁcult to
cost due to the array of insulins, wide dosing ranges, prn usage
following self testing and usage of insulin ancillaries e.g. lancets,
needles and testing strips. METHODS: Prescribing data were
collected from a longitudinal real patient database (the IMS UK
Disease Analyzer database) showing prescribing data of 650 GPs
within 130 practices across the UK providing access to 95 m
prescriptions. Costs were then assigned to the data. The popula-
tion was existing T2D patients with incidence of insulin usage,
deﬁned as those patients: Prescribed insulin with a prescription
for any oral antidiabetic drug prior to insulin and aged >40 y at
ﬁrst record of diabetes; With Read code of T2D (could include
patients <40 y); additionally incident on insulin after January 1,
2002. Costs of insulin prescriptions and ancillaries were drawn
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